Home » Previous Page » News Item:

Investors in big pharma, biotech look to ride out Trump storm

Investors in big pharma, biotech look to ride out Trump storm


Investors in large U.S. pharmaceutical and biotech companies are counting on strong dividends, reasonable stock valuations and new products to help ride out a storm of political uncertainty as the incoming Trump administration dives into healthcare policy. The sector took a pounding on Wednesday after U.S. president-elect Donald Trump said the drug industry was "getting away with murder" on medicine costs, suggesting that the specter of government actions on pricing is not going away any time soon. "We do think they are generating a lot of cash, throwing out a very nice dividend and the valuations are more reasonable than many areas of the market," said David Katz, chief investment officer at Matrix Asset Advisors in New York, which owns stock in Merck , Pfizer , AbbVie and Gilead .

Continue ...

 PDF
Tags:   Biotechnology    Investors    big    pharma    biotech    look    ride    out    Trump    storm
Rating: 0.00 (0 votes) Rate this article
Bookmark and share this news item: